Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.43 |
| ▸ | CDK4 known ✓ | P11802 | 1/20 | 0.43 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.43 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.43 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.43 |
| ▸ | CCND1 | P24385 | 1/20 | 0.43 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28319163 | 1.00 | TSHR (0.50) | TSHRAGXTIDO1ALDH1A1CA1 | |
| Hydrochloric Acid SCHEMBL27536784 | 0.98 | AGXT (0.48) | TSHRAGXTIDO1ALDH1A1CA1 | |
| SCHEMBL503 | 0.98 | TSHR (0.52) | TSHRAGXTIDO1ALDH1A1CA1 | |
| SCHEMBL901056 | 0.98 | TSHR (0.52) | TSHRAGXTIDO1ALDH1A1CA1 | |
| Benzene SCHEMBL25178056 | 0.98 | TSHR (0.52) | TSHRAGXTIDO1ALDH1A1CA1 | |
| Hno SCHEMBL27630609 | 0.96 | AGXT (0.46) | TSHRAGXTIDO1ALDH1A1CA1 | |
| SCHEMBL4515729 | 0.95 | TSHR (0.50) | TSHRAGXTIDO1ALDH1A1CA1 | |
| SCHEMBL28997098 | 0.95 | TSHR (0.50) | TSHRAGXTIDO1ALDH1A1CA1 | |
| Water SCHEMBL28793674 | 0.95 | TSHR (0.50) | TSHRAGXTIDO1ALDH1A1CA1 | |
| Fluoride SCHEMBL27488772 | 0.95 | TSHR (0.50) | TSHRAGXTIDO1ALDH1A1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110229142-A | The inhibitor of cell cycle protein dependent kinase 7 (CDK7) | 希洛斯医药品股份有限公司 | 2019-09-13 | — | — | CN | disclosed |
| CN-106458990-B | Inhibitors of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2019-06-07 | — | — | CN | disclosed |
| CN-109563033-A | Aliphatic Prolinamide derivatives | 奥瑞恩眼科有限责任公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-103874700-B | Pyrazolo [3,4-c ] pyridine compounds and methods of use | 霍夫曼-拉罗奇有限公司 | 2018-03-30 | — | — | CN | disclosed |
| CN-107051000-A | A kind of water proof material and its manufacture method and application | 徐州工程学院 | 2017-08-18 | — | — | CN | disclosed |
| CN-106458990-A | Inhibitors of cyclin dependent kinase 7(CDK7) | 希洛斯医药品股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-102718748-B | There is the compound of analgesic activities and/or Immuno-stimulant activity | 阿勒根公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-102516240-A | Heteroaryl-ureas and their use as glucokinase activators | NOVO NORDISK AS | 2012-06-27 | — | — | CN | disclosed |
| CN-101151248-B | 3-Aryl-3-hydroxy-2-aminopropionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immunostimulant activity | ALLERGAN INC | 2012-06-20 | — | — | CN | disclosed |
| CN-1910166-B | Heteroaryl ureas and their use as glucokinase activators | NOVO NORDISK AS | 2012-01-04 | — | — | CN | disclosed |
| CN-1910166-A | Heteroaryl ureas and their use as glucokinase activators | NOVO NORDISK AS (DK) | 2007-02-07 | — | — | CN | disclosed |
| CN-1108290-C | Urea derivatives | SOLVAY PHARM GMBH (DE) | 2003-05-14 | — | — | CN | disclosed |
| CN-1237178-A | Novel 'beta'-lactam compounds and process for preparing the same | SUMITOMO PHARMA (JP) | 1999-12-01 | — | — | CN | disclosed |
| CN-1218044-A | Urea derivatives | SOLVAY PHARM GMBH (DE) | 1999-06-02 | — | — | CN | disclosed |
| EP-0657163-B1 | ANTITUSSIVE | TORAY INDUSTRIES (JP) | 1998-10-14 | — | — | EP | disclosed |
| US-5739145-A | MORPHINAN DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0657163-A1 | ANTITUSSIVE | TORAY INDUSTRIES, INC. (JP) | 1995-06-14 | — | — | EP | disclosed |
| CN-1037149-A | The preparation method of 3-alkenyl-1-azabicyclo [3,2,0] hept-2-ene\"-2-carboxylic acid cpd | FUJISAWA PHARMACEUTICAL CO (JP) | 1989-11-15 | — | — | CN | disclosed |
| US-4555403-A | Pharmacologically active peptides and medicaments containing the same | BRANTL VICTOR | 1985-11-26 | — | — | US | disclosed |
| US-4390527-A | Pharmacologically active peptides and medicaments containing the same | BRANTL VICTOR | 1983-06-28 | — | — | US | disclosed |